oasis 3 semaglutide 🥼🧪Slide Deck: Efficacy and safety of oral 25 mg in adults with overweight/obesity: the 4 RCT : r/Semaglutide FDA approves once-daily oral Wegovy®

While the drug has potential dangers even when taken as prescribed, each of the risks increases at higher doses

For prescription fills exceeding a 30 day supply, we assumed supply extended across subsequent months (e.g., a 60-day fill was counted as two months of supply)

GLP-1 Loss 10% Diabetes Risk 2.6x Cardiac Risk 1.6x Sleep Apnea Risk 2.0x Your BMI is 29.2, which is higher than 38% of the population

Adjustment : The dosing schedule can be adjusted based on individual results and tolerability, as determined by the healthcare provider

PMID: 33710717 10 Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Our program includes regular check-ins, body composition analysis, and metabolic monitoring to track your progress